Search

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine.

… Wednesday, August 25, 2010 A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma . Investigators at Memorial Sloan Kettering Cancer Center and colleagues

… Monday, November 9, 2020 Miriam Lorena Murray estaba en la mejor condición física de su vida cuando recibió una desgarradora noticia: su médico le diagnosticó, cáncer de mama. “Estaba en un estado dos ya pasando a un estado tres y sin ningún síntoma, viéndome espectacular”, contó Miriam Lorena de 50

Overall survival (OS) for patients with melanoma brain metastasis treated at Memorial Sloan Kettering Cancer Center has increased significantly over the past five years, up to 13 months, according to our research published recently in Cancer.

… Thursday, November 18, 2021 Overall survival (OS) for patients with melanoma brain metastasis treated at Memorial Sloan Kettering Cancer Center has increased significantly over the past five years, up to 13 months, according to our research published recently in Cancer .  (1) This increased OS duration

The first-ever clinical trial at MSK to evaluate a novel CAR T cell therapy for AML is showing promise.

… Friday, August 29, 2025 Chimeric antigen receptor (CAR) T cell therapies have changed the way that many blood cancers are treated. A type of immunotherapy, CAR T cells redirect a patient’s own immune system in the fight against cancer. Memorial Sloan Kettering Cancer Center (MSK) has been a leader in

The funding will support patient navigation, essential needs, telemedicine, and psychosocial support services, including language translation and interpretation.

… Wednesday, September 21, 2022 The Immigrant Health and Cancer Disparities Service (IHCD) at Memorial Sloan Kettering Cancer Center (MSK) has received a five-year grant that will help advance health equity in New York and beyond. The grant, from the Merck Foundation as part of its Alliance for Equity

Dennis Chi lists the most important things to remember about ovarian cancer.

… Thursday, August 22, 2024 Ovarian cancer  is considered a rare disease. About 20,000 women in the United States will be diagnosed with it in 2024, according to the American Cancer Society. Dennis Chi, MD , Deputy Chief of the Gynecology Service and Head of Ovarian Cancer Surgery at Memorial Sloan Kettering

Learn about renowned cellular lipid and energy metabolism researchers Robert Farese, Jr., and Tobias Walther who recently joined the Sloan Kettering Institute, running their lab jointly.

… Monday, November 21, 2022 Over nearly two decades, Robert Farese, Jr., and Tobias Walther have charted a scientific partnership based on a simple formula: 1 + 1 = 3. That is, their work to illuminate the mechanisms by which cells store, maintain and use tiny droplets of energy-rich oil is more than additive

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published in The New England Journal of Medicine and presented at the 49th Annual Meeting of the American Society of Clinical Oncology.

… Sunday, June 2, 2013 The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma , according to results from a Phase I trial simultaneously published today in The New England

New MSK research finds a way to package protein-degrading drugs called PROTACs into nanoparticles that target blood vessels within solid tumors; identifies genomic markers that predict whether precancerous blood conditions will turn into multiple myeloma; develops a data-driven approach that could catch lymphedema earlier; and shows that nurse-led palliative care delivered by phone could serve as a scalable model.

… Tuesday, December 16, 2025   New research from Memorial Sloan Kettering Cancer Center (MSK) finds a way to package protein-degrading drugs called PROTACs into nanoparticles that target blood vessels within solid tumors; identifies genomic markers that predict whether precancerous blood conditions will

Dr. Diane Reidy-Lagunes speaks with Dr. John Mulhall, Director of the Male Sexual and Reproductive Medicine Program at MSK and editor-in-chief of The Journal of Sexual Medicine, to discuss the impacts of cancer and its treatment on men’s sexual health.

… Thursday, March 3, 2022 Men’s sexual dysfunction is common during cancer treatment, so why doesn’t anyone talk about it? The medical team treating a cancer too often fails to address the potential impact on the patient’s sex life, despite the fact that it can be essential for emotional well-being. If